logo-loader
RNS
viewMaxCyte Inc

Editas Clinical and Commercial License Agreement

/**/ sup{font-size:80%}h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Calibri","sans-serif";color:#365F91;font-weight:normal;}h2{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:13.0pt;font-family:"Calibri","sans-serif";color:#365F91;font-weight:normal;}p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ae{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 64.8pt 72.0pt;}div.ae{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";}span.bo{font-family:"Times New Roman","serif"; color:red}span.bn{font-family:"Times New Roman","serif"; color:black;background:white}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; text-align: center}span.bm{font-family:"Times New Roman","serif";color:black;background:white}p.br{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify;background:white}span.bk{font-family:"Times New Roman","serif";color:black;background: white}span.bj{font-family:"Times New Roman","serif"; color:black} span.bh{font-family:"Times New Roman","serif";color:black}span.bi{background:white}span.bg{font-family:"Times New Roman","serif"}p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";text-align:justify}p.bt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";background:white}span.bd{font-family: "Times New Roman","serif";color:black}p.bu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif"; font-weight: bold}span.ba{font-family:"Times New Roman","serif"; background:white}span.az{font-family:"Times New Roman","serif";background:white}p.bv{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold; text-align: justify} p.bf{text-align:justify;background:white}span.ax{color:black}span.aw{color:black; background:white}span.av{color:black;background:white}p.bw{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";font-weight: bold}span.au{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.bx{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";text-align: center}table.by{width:456.3pt;border-collapse:collapse;border:none}tr.ap{height:14.05pt}td.ar{width:242.8pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.05pt} td.aq{width:191.9pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:14.05pt}td.ao{width:242.8pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:14.05pt}td.an{width:191.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:14.05pt}tr.aj{height:92.7pt}td.al{width:242.8pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:92.7pt}p.bz{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Cambria","serif";font-div: italic; font-weight: bold}td.ak{width:191.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:92.7pt}tr.ag{height:101.25pt}td.ai{width:242.8pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:101.25pt}td.ah{width:191.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:101.25pt} /**/
RNS Number : 9473O
MaxCyte, Inc.
07 October 2019
 


Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

 

CAMBRIDGE, Mass., and GAITHERSBURG, Md., October 7, 2019 - Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc. (LSE: MXCT, MXCS), the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte's Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia.

 

Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies, and in return MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.

 

"We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.

 

"We are excited to work with Editas Medicine as it is at the forefront of developing engineered cell medicines that have the potential to change the course of disease for many patients. This agreement is also a significant business milestone for MaxCyte as we continue to invest in our technology platform and help support companies at the leading edge of cell therapy and gene editing to develop medicines for patients in need," said Doug Doerfler, President & CEO of MaxCyte, Inc.

 

MaxCyte's ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

 

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com

 

About MaxCyte 

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six commercial licenses. Aggregate potential pre-commercial milestones from all previously announced license deals total more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

 

Editas Medicine Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Editas Medicine may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.  Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Editas Medicine's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for Editas Medicine's foreseeable and unforeseeable operating expenses and capital expenditure requirements.  These and other risks are described in greater detail under the caption "Risk Factors" included in Editas Medicine's most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission, and in other filings that Editas Medicine may make with the Securities and Exchange Commission in the future.  Any forward-looking statements contained in this press release speak only as of the date hereof, and Editas Medicine expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

###

 

 Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Editas Medicine

Media

Cristi Barnett

 

+1 (617) 401-0113

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

James Stearns

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

+44 (0)20 7260 1000

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

 

+44 (0)203 709 5700

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRCKODNPBDKAKK

Quick facts: MaxCyte Inc

Price: 120

Market: AIM
Market Cap: £68.87 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18